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Abstract: Multi-omics strategies are indispensable tools in the search for new anti-tuberculosis
drugs. Omics methodologies, where the ensemble of a class of biological molecules are measured
and evaluated together, enable drug discovery programs to answer two fundamental questions.
Firstly, in a discovery biology approach, to find new targets in druggable pathways for target-based
investigation, advancing from target to lead compound. Secondly, in a discovery chemistry approach,
to identify the mode of action of lead compounds derived from high-throughput screens, progressing
from compound to target. The advantage of multi-omics methodologies in both of these settings is
that omics approaches are unsupervised and unbiased to a priori hypotheses, making omics useful
tools to confirm drug action, reveal new insights into compound activity, and discover new avenues
for inquiry. This review summarizes the application of Mycobacterium tuberculosis omics technologies
to the early stages of tuberculosis antimicrobial drug discovery.
Keywords: mycobacterium; tuberculosis; drug discovery; genomics; transcriptomics; proteomics;
metabolomics; lipidomics; target identification; mechanism of action; antimicrobial drug resistance
(AMR)
1. Introduction
Tuberculosis (TB) remains one of the top 10 causes of death worldwide, with 10 million new cases
and 1.4 million deaths in 2018. The problem of antimicrobial drug resistance (AMR) is rising, with drug
resistance associated with 3.4% of new TB cases globally and up to 50% of previously treated cases in
some areas of the world [1]. The discovery of new drugs to treat Mycobacterium tuberculosis (M.tb) is
challenging, with only pretomanid, delamanid and bedaquiline marketed for use in the last 40 years
despite sustained international efforts [2]. Multiple logistical and physiological factors contribute to
the difficulty of this task (reviewed eloquently elsewhere [3–5]). They include biosafety constraints of
working with a slow-growing pathogenic bacterium, heterogeneity of clinical disease and bacterial
phenotypes in vivo, intracellular and extracellular M.tb sites, drug penetration into lung pathology, the
lipid-rich M.tb cell wall as a barrier to drug uptake and intrinsic drug resistance, limited number of
validated drug targets, the requirement for combination drug therapy, and the length and cost of clinical
trials. Omics technologies aim to measure and evaluate together the ensemble of molecular entities by
biological class to understand the contribution of each component. Whatever the category of molecule
under investigation, the key advantage of omics approaches is that they are unsupervised, and thus
less biased by dogma, which is valuable for overcoming drug development bottlenecks [6,7]. Omics in
a hypothesis-generating discovery biology setting, is an excellent means of identifying new targets for
drug discovery. In a compound-first (discovery chemistry) approach, liberated from reductionist assays,
omics technologies are useful tools to reveal or confirm drug mode of action. Mycobacterial omics are
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applicable throughout the drug development process from initial drug discovery to preclinical and
clinical stages, at each step describing the action of compounds, derivatives, and formulations on M.tb.
For example, identifying target drift or off-target effects during lead optimization, or characterizing
drug resistance conferring mutations in clinical trials.
This review summarizes the application of M.tb omics strategies in the early stages of the
discovery of new drugs for TB, incorporating genomics (DNA), transcriptomics (mRNA), proteomics
(proteins), metabolomics (metabolites) and lipidomics (lipids). The review is not intended to be
comprehensive—omics are now fully established in most drug discovery settings—but aims to
highlight landmark and interesting approaches to the TB drug development problem. The review
centers on omics applied directly to M.tb, using examples from other mycobacterial models only to
illustrate groundbreaking discovery tools. We focus on (a) target identification, in this context the
recognition of potentially druggable pathways worthy of drug discovery efforts in a target-based
approach; (b) mode of action studies, often aimed at progressing hits from whole cell compound
screening strategies on the long road to the TB clinic (Figure 1).
Figure 1. The application of omics tools to antimicrobial drug discovery pathways. In a discovery
biology approach, omics methodologies are used early in the process to identify new targets for
investigation. In a discovery chemistry setting, omics techniques are useful further down the road to
identify mechanism of action of lead compounds.
2. Genomics
2.1. Target Identification
The M.tb H37Rv genome was sequenced in 1998, revealing ~4000 potential drug targets, of which
~50% were assigned a tentative function [8,9]. M.tb H37Rv was selected for sequencing as the type
strain for M.tb. M.tb H37 was isolated from a patient in 1905 and serially passaged in the laboratory,
a resulting strain was named H37Rv, with “R” standing for rough morphology and “v” for virulent [8].
It has become a commonly used laboratory strain of pathogenic M.tb, a genomic reference for clinical
isolates, and a starting point for drug discovery. Since then, comprehensive whole genome sequencing
of M.tb clinical isolates recovered from patients with TB has uncovered a core genome and mapped the
accumulation of single nucleotide polymorphisms (SNPs) in protein coding genes [10]. Comparative
genomics has also enabled drug specificity (across microbial species) and toxicity (to mammals) to be
anticipated, based on the presence or absence of target protein coding sequences. The application of
genomics to M.tb has therefore provided a framework of potential drug targets. Manipulation of gene
function, through gene inactivation strategies, has aided recognition of pathways that are essential to
M.tb in different microenvironments, thus highlighting targets for drug discovery programs [6].
Gene deletion methods designed to generate unmarked single gene knockout mutants have
been employed alongside global approaches using transposons (Tn) to inactivate gene function [11].
Tn libraries are generated by disrupting genes through random insertion of a transposon throughout the
genome, then applying a selective pressure to measure gene essentiality. DNA microarrays were initially
used to map the changing abundance of thousands of Tn mutants, transposon site hybridization
(TraSH) [12]; more recently coupled to whole genome sequencing (Tn-seq) for greater genomic
resolution [13]. Tn mutant screening has been used to map the genetic pathways required for growth
of M.tb and Mycobacterium bovis Bacillus Calmette-Guérin (BCG) in vitro [14]. Here, a Himar1 based Tn
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delivery method using a transducing bacteriophage generated a library of ~100,000 independent clones.
A total of 614 genes essential for in vitro growth were found to be evenly distributed throughout the
mycobacterial chromosome. In addition, many genes that were shown to be essential for growth
appeared to be co-transcribed in operons. Essential genes were identified in amino acid, co-factor and
nucleic acid biosynthesis pathways; genes of unknown function were also classified as essential.
Many genes assumed to be essential that were predicted to be involved in cell wall and protein
metabolism were shown to be dispensable. This is likely due to functional redundancy; for example,
purT and purN both offer alternative pathways for purine de novo biosynthesis and so neither gene
was essential [15], providing valuable information that allows non-essential targets to be dropped from
drug discovery portfolios. A fundamental pathogenic trait of M.tb is the ability to survive and replicate
in phagocytes, avoiding phagosome-lysosome fusion and adapting to an intracellular lifestyle [16].
Therefore, to define pathways that are essential for intra-macrophage survival, Barczak et al. mapped
genes required for intracellular growth using high content imaging alongside multiplexed cytokine
analysis of macrophages infected with M.tb Tn mutant libraries [17]. Systematic, multiparametric
analysis of M.tb Tn mutants impaired for intracellular growth identified functional relationships
between M.tb Tn mutants and macrophage cytokine profiles. The authors showed that production
and export of the complex lipid, phthiocerol dimycocerosate (PDIM), was required for the secretion
of ESX-1 substrates and permeabilization of the phagosome, revealing key virulence determinants,
alongside defining pathways that are essential to the metabolism of intracellular bacilli, identifying
potential targets for drug discovery. Plainly, Tn mutant libraries will only identify genes that are
essential in the model under investigation, successful drug targets are likely required to be essential
across several different conditions to mimic the variety of microenvironments encountered by M.tb
during natural infection.
Gene deletion or inactivation results in the absence of gene product, this may not be reflective of
drug action, where complete inhibition of protein function may not occur [18]. Conditional expression
strategies that reduce rather than abrogate protein function may better represent drug action,
and crucially allows essential gene targets to be investigated in the laboratory. Conditional expression
using inducible promoter systems (for example, Tet ON/OFF or Pip ON/OFF) allow the expression of
essential genes to be increased or reduced to understand gene function, model drug target inhibition
and genetically-validate drug targets. The utility of such an inducible gene expression system was
highlighted by Johnson et al. where M.tb mutants depleted for 474 essential genes (termed hypomorphs)
were screened against a large pool of potential inhibitors, allowing for >8.5 million chemical-genetic
interactions to take place [19]. An episomally-encoded sspB gene was introduced to control protein
degradation via a carboxyl-terminal fused DAS-tag. In addition, a 20 nucleotide “barcode” was
introduced to facilitate enumeration by sequencing the barcoded PCR products derived from the
mutants when pooled. The expression of SspB was controlled by a TetON promoter that was induced
in response to anhydrotetracycline; by using TetON promoters with varying strengths, the level
of gene product targeted for degradation by the SspB gene could be titrated. Primary screening
using this hypomorph methodology identified over 10-fold more hits than whole cell screening wild
type M.tb. As expected, well known antimicrobial drug classes showed interactions with specific
hypomorphs, such as fluoroquinolones with their target GyrA, as well as rifampicin with the β subunit
of RNA polymerase. This screening approach identified 39 inhibitors that targeted cellular components
that are already clinically-validated antimicrobial drug targets; DNA gyrase, mycolic acid synthesis,
and folate biosynthesis, targeted by the fluoroquinolones, isoniazid, and para-amino-salicylic acid,
respectively [20]. The 39 compounds were either novel chemical entities or known compounds with
re-purposed activity, such as the plant alkaloid tryptanthrin. In addition to finding novel inhibitors for
well-validated targets, hypomorph screening also identified inhibitors against novel cellular targets.
Johnson et al. demonstrated that strains hypomorphic for the putative efflux pump EfpA were inhibited
by the compound BRD-8000 (MIC 6 µM) but this compound showed no activity against wild type M.tb
(MIC ≥ 50 µM). Subsequent chemical optimization improved activity of BRD-8000 against wild type
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M.tb to an MIC of 800 nM, an increase of ≥63-fold activity. M.tb spontaneous mutants resistant to this
modified BRD-8000 compound showed a single point mutation in efpA, demonstrating that chemical
modification of BRD-8000 had not altered target specificity.
Clustered Regularly Interspaced Short Palindromic Repeats interference (CRISPRi) has the
potential to revolutionize the field, enabling precise gene silencing to identify and validate drug
targets. A nuclease, dCas9 containing two mutations that eradicate its nuclease activity, is targeted to a
mycobacterial gene of interest by a single guide RNA (sgRNA). Upon binding of the dCas9-sgRNA
complex to the target site, the DNA duplex destabilizes and prevents gene transcription by blocking
RNA polymerase promoter access [21]. Notably, the level of gene silencing can be controlled by varying
the sgRNA length and sequence, this allows fine control of the expression of essential genes where
traditional gene knockout approaches would be lethal. This system has been further optimized to be
induced by doxycycline. This is a lipophilic drug with excellent tissue penetration properties, so that
CRISPRi can be employed across a range of drug screening models including in vitro, intracellular
and animal studies [22,23]. This approach was used to create libraries containing over 90,000 sgRNAs,
generating pools of M.tb strains where the majority of genes have been targeted by CRISPRi, enabling
high throughput screening approaches to be applied. The utility of CRISPRi in target-based drug
discovery was demonstrated through gene silencing of folate metabolism [24]. M.tb and mammals
require folate; however, M.tb must synthesize folate de novo while mammals obtain it through their diet.
The variation in folate metabolism makes this biosynthetic pathway an attractive target for antimicrobial
drug discovery [25]. While this pathway has been targeted in other bacteria with the antimicrobial
drugs trimethoprim, inhibiting dihydrofolate reductase (FolA), and sulfamethoxazole, inhibiting
dihydropteroate synthase (FolP1); the action of these drugs in mycobacteria is less clear. Generation of
folate biosynthesis knockout mutants in mycobacteria has proved challenging, making target validation
difficult for this pathway. Mycobacterium smegmatis is a non-pathogenic mycobacterium frequently
used as a model organism for M.tb due to its low biohazard risk and tractable genomics [26]. Rock et al.
utilized a panel of sgRNAs to generate hypomorphs of folP1, folA and folC (dihydrofolate synthase) in
this model organism to show that these genes were individually essential. If weaker sgRNAs were used
to decrease growth rate rather than inhibit growth completely, there was synergistic growth inhibition,
demonstrating the utility of exploiting multiple targets in this pathway to maximize antimicrobial
drug activity. Translation of the technology to M.tb will yield useful insights into target and pathway
essentiality. One caveat to CRISPRi is the potential for off target effects, where dCas9 binds and silences
genes that were not intended to be targeted. Bioinformatics packages exist that effectively predict this
binding; however, these algorithms may not capture every off-target event [27,28].
2.2. Mode of Action
Advances in next generation sequencing technologies and the continued reduction in cost has
placed whole genome sequencing (WGS) firmly into the drug discovery pipeline from mechanism of
action identification through to monitoring drug resistance post approval [29]. Illumina sequencing
(Illumina Inc., San Diego, CA, USA) generates short sequence reads (typically 150 bp long), and while
the majority of sequencing data generated today is from Illumina platforms, alternative methodologies
are also useful to antimicrobial drug discovery. Long read sequencing (~kilobases), available through
platforms such as PacBio (Pacific Biosciences, Menlo Park, CA, USA) and Oxford Nanopore
(Oxford Nanopore Technologies Ltd, Oxford, UK), are especially suited for sequencing repetitive regions
and structural variations. WGS has been exploited to identify mutations that occur in spontaneous
drug resistant colonies growing on solid agar containing a novel antimicrobial compound of interest,
typically between 5-fold and 10-fold the minimum inhibitory concentration. Using drug exposure as
the selective pressure, this methodology may reveal mutations that affect drug action, in the drug target
itself or in gene functions that influence drug activation or efflux. Andries et al. in the discovery of
bedaquiline, employed WGS of M. smegmatis and M.tb bedaquiline-resistant mutants cultured in vitro
to demonstrate that this diarylquinoline targets the product of atpE; a subunit of the mycobacterial
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ATP synthase anchored in the mycobacterial membrane [30]. Kundu et al. further characterized
this mode of action, showing that bedaquiline binds to the epsilon subunit [31]. Mutations can,
however, be identified in other non-target genes that confer resistance, expanding understanding
of drug action but complicating the interpretation of results. For example, in a murine model of
TB infection, mutations in the putative Xaa-Pro aminopeptidase pepQ were identified that conferred
low level resistance to both bedaquiline and clofazimine, neither of which target PepQ directly [32].
While the function of PepQ remains to be determined in M.tb, Almeida et al. postulated that this
mutation prevented protein degradation of the efflux pump MmpL5, enhancing drug efflux and
inducing resistance to bedaquiline and clofazimine [32].
WGS has also been used to reveal the mechanism of action of repurposed licensed pharmaceuticals
in M.tb. Rybniker et al. identified lansoprazole from the Prestwick library of 1280 FDA approved drugs
as protective to lung fibroblasts in an M.tb intracellular model of infection [33]. Three lansoprazole
resistant mutants were sequenced; each mutant showed the same SNP, a substitution of leucine for
proline, in the β-subunit of the cytochrome bc1 complex gene qcrB, a key element of the mycobacterial
respiratory chain. To demonstrate that exposure to this commonly prescribed proton pump inhibitor
did not select for lansoprazole-resistant M.tb, Rybniker et al. sequenced 13,559 M.tb Complex clinical
isolates revealing only one M. bovis isolate with a mutation in qcrB [34]. Of course, this methodology
to define the target of drugs with unknown mechanisms of action is only fruitful if drug-resistant
colonies can be raised, which is not always the case. This was highlighted in the discovery of the novel
antimicrobial drug, teixobactin from the bacterium Eleftheria terrae. Here, a novel iChip culture method
was used to capture previously unculturable bacteria in their natural soil environment, which led to
the identification of the cell wall-targeting agent teixobactin [35]. Neither Staphylococcus aureus nor
M.tb drug resistant colonies could be generated even at sub-inhibitory concentrations. The authors
hypothesized that this indicated general cell toxicity of the compound; however, no mammalian
cell toxicity was observed. Subsequent biochemical approaches indicated that this compound
exerted its antimicrobial effects through interactions with peptidoglycan pre-cursors—mostly lipid II.
Therefore, the inability to generate spontaneous resistance in vitro is likely due to teixobactin inhibiting
multiple non-protein targets. Like many other antimicrobial drugs, teixobactin was isolated from an
environmental microorganism. It is therefore possible that bacteria in close proximity to E. terrae in
the soil may be resistant to teixobactin, offering a scenario where teixobactin resistance mechanisms
could be discovered [36]. While the inability to detect drug resistance in the laboratory does not
mirror the complexity of TB clinical disease alongside host pharmacokinetic and pharmacodynamic
factors, the concept of resistance-proof antimicrobial drugs is very attractive and could transform the
destructive antimicrobial drug to evolution of drug resistance cycle.
WGS is also shaping our understanding of drug action and drug resistance through the large-scale
sequencing of clinical isolates. Consortia mapping drug-resistance conferring mutations have revealed
novel mechanisms of resistance and potential novel modes of action of existing anti-M.tb drugs in
patients [37]. The CRyPTIC Consortium and the 100,000 Genomes Project obtained over 10,000 M.tb
clinical isolate genomes and associated phenotypes to predict phenotypic drug susceptibility to front
line agents from genome sequence. The authors successfully demonstrated that susceptibility could
be correlated to the presence or absence of specific antimicrobial drug resistance mutations [37].
This approach also exposed mutations with as yet unexplained roles in drug action. For example,
M.tb isolates have been identified with mutations in the mycothiol biosynthetic genes mshA and mshC
that confer high-level resistance to ethionamide and low-level resistance to isoniazid [38]. Mycothiol
is a key detoxifying and reducing molecule with similar functions to glutathione, which is absent in
mycobacteria [39]. Knockout mutants of mshA grew normally in vitro and in immunodeficient mice
but were growth defective in immunocompetent mice [40], and mycothiol-deficient mutants were
less susceptible to ethionamide and isoniazid [41]. Ethionamide and isoniazid are both prodrugs that
target the NADH-dependent enoyl-ACP reductase InhA; however, isoniazid is activated by KatG
and ethionamide by EthA [42,43]. In order to delineate the roles mycothiol biosynthetic genes play
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in isoniazid and ethionamide susceptibility, Xu et al. generated null mutants of each mycothiol
biosynthetic gene in M. smegmatis [44]. M. smegmatis is useful for studying the action of these
two drugs, with their target InhA characterized in this bacterium to have >95% sequence identity
to the M.tb InhA [45]. While the exact role of mycothiol in isoniazid and ethionamide resistance
remains to be determined, the authors hypothesized that mycothiol is involved in the activation of
isoniazid and ethionamide. M.tb KatG, required for isoniazid activation, likely compensates for loss of
mycothiol in some settings, resulting in isoniazid susceptibility and ethionamide drug resistance in
mycothiol-deficient isolates [40]. Understanding the action of current M.tb drugs has direct implications
for the development of new inhibitors. For example, bedaquiline and clofazimine resistance can be
mediated through SNPs in Rv0678, a transcriptional repressor of mmpL5 and mmpS5, which encode an
efflux pump of the resistance-nodulation-division (RND) family [46,47]. SNPs in Rv0678 were detected
in clinical isolates of M.tb with no prior exposure to bedaquiline or clofazimine [48]; meaning that
resistance to bedaquiline was already circulating in M.tb isolates before the new drug was introduced
to the TB clinic. While the authors could not determine the driver of these mutations, they ruled out
rifampicin as a selective pressure. Studies such as these are revealing drug detoxification and efflux
pathways that operate across drug class to reduce efficacy of both existing and new antimicrobial drugs.
To expand the methods available for understanding drug mechanism of action, Melief et al.
constructed a library of M.tb strains overexpressing single genes that could be screened in a
high-throughput format [49]. It was hypothesized that library mutants overexpressing the target of an
antimicrobial drug should be more resistant than wild type M.tb to that particular drug. The library was
constructed cloning each gene downstream of a tetracycline-inducible promoter. The 1733 constructs
covered 40% of protein coding genes in the M.tb genome and contained the majority of annotated
essential genes, as well as genes involved in cell wall and fatty acid biosynthesis, virulence factors,
regulatory proteins and efflux. The functionality of the system was confirmed by screening the
library for resistance to D-cycloserine, which identified the Alr-over-expressing mutant as the only
recombinant strain that grew in the presence of the drug. Over-expression of Alr, a target of the drug,
resulted in a 7-fold increase in the minimum inhibitory concentration of D-cycloserine. This library
represents a new tool to discern targets and pathways that influence drug efficacy of lead compounds
with unknown mechanisms of action.
3. Transcriptomics
3.1. Target Identification
Understanding the mycobacterial transcriptome is key to connecting genome information to
protein target expression, highlighting potentially druggable pathways and bacterial responses to
drug exposure. With the development of whole-genome technologies, such as microarrays and more
recently RNAseq, gene expression studies have been able to capture a snapshot of the total abundance
and differential expression of transcripts present in an organism in various conditions. Transcriptomics
has become an important tool for exploring the biology of M.tb, providing information about adaptive
responses to understand mechanisms of pathogenicity, assign gene function, discover new drug targets
and explore drug action. Transcriptomics in a discovery biology setting has uncovered induction
of potentially druggable pathways involved in β-oxidation of fatty acids, the glyoxylate shunt and
cholesterol metabolism in M.tb replicating intracellularly in macrophages [50,51] and in expectorated
M.tb in patient sputa [52], alongside expression of metal detoxification systems [53,54] amongst
others. Profiling in vitro models of persistence has revealed adaptations to respiratory and metabolic
networks involved in the transition of M.tb between different growth states [55,56] highlighting target
pathways for investigation. RNA signatures from animal models of TB infection [57,58] and human
tissue [59] provide important information on the expression of targets in human disease, enhancing
the prospect of cidal drug action by targeting pathways active in vivo. This is valuable evidence for
drug discovery decision making, since the bactericidal or bacteriostatic inhibition of an essential target
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in vitro does not necessarily predict in vivo drug efficacy. This was demonstrated by Pethe et al. who
identified pyrimidine-imidazoles as potent antimycobacterial agents in a whole cell screen against
M.tb; lead compounds showed activity in vitro but failed to show any inhibition in a murine model
of infection [60]. Compound efficacy was linked to the accumulation of glycerol phosphate and a
reduction in ATP synthesis in the presence of glycerol. Glycerol metabolism is dispensable in vivo and
thus inhibition of this pathway was not cidal in animal models of TB disease. Approaches combining
transcriptomic and gene essentiality datasets offer a multi-omics solution to prioritizing pathways for
further investigation.
3.2. Mode of Action
The transcriptional response of M.tb to antimicrobial drug exposure has improved the
understanding of many drugs, providing new insights for antibiotics currently in use for TB treatment
with known cidal mechanisms, as well as predicting mode of action and the targets of novel compounds.
This unsupervised approach is especially useful for understanding the actions of lead compounds from
high-throughput screens where the mechanism of M.tb killing is entirely mysterious. Comparison of
the M.tb transcriptional response to a novel compound with mRNA signatures derived from drugs
of known function allows broad mode of action to be revealed (Figure 2). In the first study of M.tb
transcriptional adaptations to drug treatment, Wilson et al. used DNA microarrays to explore changes
in gene expression in response to isoniazid [61]. The authors showed that drug exposure induced
several genes relevant to isoniazid’s known mode of action; drug treatment caused the cluster of five
genes encoding type II fatty acid synthase enzymes (fabD-acpM-kasA-kasB-accD6) to be upregulated.
Other induced genes, such as efpA and ahpC not in the biosynthetic pathway targeted by isoniazid,
were linked to the toxic effects of the drug. In subsequent years, several studies have used DNA
microarrays to correlate the mRNA signatures of M.tb exposed to antimicrobial drugs with predicted
mode of action [62–64]. Boshoff et al. generated a dataset of 430 M.tb gene expression profiles to
measure the effect of 75 different drugs, drug combinations and growth conditions [64]. The individual
RNA drug signatures were classified into groups of agents with similar modes of action (protein
synthesis inhibitors, transcriptional inhibitors, cell wall synthesis inhibitors and DNA damaging
agents), which have been used to predict the mechanism of action of antimycobacterial compounds of
unknown function derived from whole cell screening approaches [65–68].
Figure 2. The application of transcriptomics to define drug mode of action. Principle Component
Analysis (PCA) of M.tb responses to seven different drugs (represented by shapes) derived from
RNAseq of 2–3 biological replicates per drug. M.tb mRNA signatures from antimicrobial drugs with
similar mechanisms of action will cluster together.
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Transcriptomics has been applied to investigate the mode of action of drugs now in phase I/II
studies or in the clinic [2]. The M.tb transcriptional signature to benzothiazinone exposure most
resembled that of cell wall inhibitors and ethambutol in particular, providing an early indication that
the compound was targeting cell wall biosynthesis and arabinogalactan synthesis. This was confirmed
to be the case with benzothiazinones inhibiting decaprenyl-phosphoribose-2′-epimerase (DprE1) in
the metabolism of D-arabinose, two steps upstream of the action of ethambutol [7]. RNA profiling
provided fundamental insights to elucidate the molecular mechanism of mycobacterial killing by
pretomanid (formerly PA-824), a nitroimidazole active against both replicating and non-replicating
M.tb, by inhibiting cell wall synthesis and releasing nitric oxide [69,70]. Pretomanid exposure resulted
in a dual signature indicating cell wall inhibition (similar to isoniazid) and respiratory chain disruption
(similar to respiratory inhibitors such as cyanide). While the upregulation of genes such as fasI, the fasII
operon, efpA and iniBAC signposted the aerobic killing mechanism targeting cell wall biosynthesis,
drug efficacy in anaerobic conditions was marked by the induction of the cyd operon encoding the
non-proton-pumping cytochrome bd oxidase, the nitrate reductase narGHIJ and other genes involved
in respiration [71]. RNAseq analysis of the M.tb response to the recently approved nitroimidazole
delamanid (formerly OPC-67683) showed many similarities to the pretomanid signature, highlighting
that respiratory poisoning plays an important role in the bactericidal effect of these compounds in
anaerobic conditions [72].
Boot et al. used RNAseq responses of M.tb and Mycobacterium marinum to subinhibitory
concentrations of ciprofloxacin, ethambutol, isoniazid, streptomycin and rifampicin to select genes
to act as drug mode of action-specific reporters [73]. Concordance between the expression levels of
M.tb and M. marinum upon drug exposure were high for the orthologous genes; however, M. marinum
showed a more distinct stress fingerprint that facilitated simple assays for quick mode of action
determination. Ten drug-specific M. marinum genes were selected and their promoter regions were
cloned into green fluorescent protein (GFP) reporter constructs. As proof of concept that these drug
reporters could accelerate TB drug discovery by identifying the mode of action of hit compounds,
the MMAR_4645-ciprofloxacin reporter and iniBAC-isoniazid reporter were used to screen a library
of 196 antimycobacterial compounds. The screening revealed two compounds to have a mode of
action similar to isoniazid, likely targeting the mycobacterial cell wall, and one compound, similar to
ciprofloxacin, that potentially inhibited DNA replication. Understanding mycobacterial responses
to antimicrobial drugs may also offer new targets to enhance combination therapy. Peterson et al.
used the Environment and Gene Regulatory Influence Network (EGRIN) model and Probabilistic
Regulation of Metabolism (PROM) model of M.tb regulatory systems to demonstrate that bedaquiline
pushed bacilli into a tolerant state that reduced bedaquiline killing [74]. Disruption of this network,
by knocking out key transcription factors (Rv0324 and Rv0880) predicted to mediate this response,
significantly increased bedaquiline killing. Analysis of transcriptome data from M.tb exposed to
antitubercular drugs identified molecules that significantly downregulated the expression of Rv0324
or Rv0880, predicting synergism between bedaquiline and pretomanid through the inhibition of the
Rv0880 regulon by pretomanid. The in vitro combination of sub-inhibitory concentrations of both
drugs showed an additive to mildly synergistic effect, while the effect was eliminated and a strong
antagonism observed when the combinations were tested using a strain over-expressing Rv0880.
Given the vast number of possible drug combinations, this strategy could complement other preclinical
methods and accelerate the discovery of new drug regimens for TB by avoiding combinations with
antagonistic interactions and prioritizing those with synergistic effects.
The interaction between drugs in combination were also explored in the computational model
INDIGO-MTB, with the premise that drug synergy and antagonism occur due to coordinated,
system-level molecular changes involving multiple cellular processes [75]. Using a compendium of
publicly-available and in-house M.tb transcriptional responses to drug exposure in vitro as input,
the model screened in silico more than 1 million potential combinations of 164 drugs, predicting
synergistic and antagonistic regimens featuring 35 existing and potential anti-TB drugs. Combinations
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containing chlorpromazine, a drug used to treat psychiatric disorders, and verapamil, used to
treat hypertension, were highly enriched for synergistic interactions. In contrast, combinations
featuring sutezolid, an oxazolidinone anti-TB drug in phase II trials, were observed to be antagonistic.
Regimens featuring combinations of bacteriostatic and bactericidal drugs, and combinations of
only bactericidal drugs, had significantly more antagonistic interactions than combinations of only
bacteriostatic drugs. The predictions of INDIGO-MTB were validated experimentally in vitro using
checkerboard assays and the high-throughput DiaMOND method and compared to a meta-analysis of
data assembled from 57 phase II clinical trials. The authors found a significant correlation between
INDIGO-MTB interaction scores for drug regimen synergy and sputum culture conversion rates after
8 weeks of treatment. The model also identified Rv1353c as a key transcriptional regulator mediating
multiple drug interactions. The upregulation of Rv1353c in vitro reduced drug antagonism of the
bedaquiline-streptomycin combination, suggesting this transcriptional factor might be targeted to
enhance drug synergies.
Most transcriptional profiling studies map the response of log phase aerobically-respiring bacilli
to drug exposure in vitro, this enables direct comparison between drug signatures from axenic culture,
but misses the complexity of M.tb in vivo phenotypes. Studies by Walter et al. and Honeyborne et al.
have characterized drug responses in patient sputa during standard therapy as a measure of in-patient
drug efficacy, identifying, for example, an isoniazid signature in expectorated bacilli that disappears
after only 3-4 days of the start of drug therapy [76,77].
4. Proteomics
4.1. Target Identification
Due to limitations in the sensitivity of methods and in the complexity of analysis, proteomics is yet
to reach the multifaceted scope of genomics and transcriptomics approaches [78]. However, the variation
between protein abundance and corresponding mRNA abundance, suggests that proteomics provides
a distinct and useful understanding of M.tb physiological responses and target expression [79].
A number of studies have revealed insights into the expression of M.tb proteins intracellularly and
in vivo, confirming the expression of potentially druggable targets. There are broadly two proteomics
strategies, firstly, a top-down approach whereby intact proteins are isolated from a biological sample
and sorted by gel electrophoresis, based on their physical and chemical properties, before identification
by mass spectrometry (MS) [78]. Popular in early proteomic research, this technique typically found
~100 mycobacterial proteins, accounting for approximately 3% of the total M.tb proteome. The second
approach is the bottom-up method, where a total set of proteins are proteolytically cleaved into peptides,
followed by high-performance liquid chromatography and tandem mass spectrometry (LC-MS/MS).
This strategy may quantify many more proteins and track a predefined subset of proteins to greater
sensitivity, however computational resolution of profiles and insufficient sensitivity currently limits
proteomics discoveries [78]. Despite the lag in proteomics compared to other omics, several studies
have revealed new insights into mycobacterial protein expression. Målen et al. compared expression
of M.tb H37Rv and M.tb H37Ra membrane proteins using gel electrophoresis and in-gel digestion of
proteins followed by MS [80]. The authors identified over 1700 proteins expressed in both strains,
29 of which were membrane-associated proteins with >5-fold difference in abundance between
strains. This highlighted expression of potentially druggable proteins associated with transmembrane
transport, complementing genomics and transcriptomics approaches to confirm presence of target
protein, and mapped the expression of efflux systems that might impact drug efficacy. Isobaric tagging
and stable isotope labelling have enhanced the identification and quantification of proteins by mass
spectrometry, enabling more efficient mapping of peptides to protein and allowing comparative
samples to be analyzed simultaneously [81]. Thompson et al. quantified N-terminal acetylation of
cytosolic and secreted proteins in M.tb and M. marinum using an N-terminal enrichment approach
coupled with stable isotope ratio mass spectrometry [82]. The authors identified 211 endogenously
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N-terminally acetylated proteins in M.tb (11% of the total observed proteome); 31.8% of these proteins
were involved in intermediary metabolism and respiration, indicating the importance and abundance
of protein acetylation in mycobacteria. A difference in acylation level was detected in cytoplasmic
and secreted forms of 16 mycobacterial proteins, suggesting that N-terminal acetylation might affect
protein localization. Acetylation was linked to the secretion of virulence factors (ESX substrates)
and antimicrobial drug detoxification systems, signifying N-terminal acetylation as a potentially
druggable pathway in M.tb. Whilst this approach is clearly beneficial for the detection of acetylation in
mycobacteria, consideration should be taken when selecting strains and growth conditions, since these
factors will impact protein enrichment resulting in variation between studies, as demonstrated by the
authors when comparing the proteome of H37Rv with the published literature.
Proteomics has been applied to in vitro models of infection to find new targets for drug discovery.
Albrethsen et al. combined label-free LC-MS/MS and 2D difference gel electrophoresis to reveal
extracellular proteins produced by M.tb under nutrient starvation [83]. The authors identified
proteins involved in toxin-antitoxin (TA) systems, suggesting a role for these systems in the
switch from active to non-replicating metabolic states and proposing that TA systems should be
explored as potential therapeutic targets. Despite RNAseq often being the preferred approach
for such investigations, applying proteomics revealed information regarding protein localization,
binding preferences and post-transcriptional modifications that would not be generated from an
mRNA analysis. M.tb protein expression has been mapped during intracellular infection of alveolar
epithelioid cells and macrophages [84]; comparison of the M.tb protein expression profiles in these
two cell types identified 6 mycobacterial proteins that were differentially expressed in epithelioid cells.
Kruh et al. investigated M.tb protein expression in vivo, identifying 500 unique M.tb proteins that were
expressed in the lungs of guinea pigs [85]. Most abundant were M.tb proteins implicated in cell wall
function and respiration, providing a rational basis for targeted drug discovery against these pathways
active during infection.
4.2. Mode of Action
Proteomics has helped to deconvolute M.tb responses to drug exposure providing insight into
mechanisms of drug action and resistance [86]. Recently, Meneguello et al. used proteomics to
explore the metabolic pathways that contribute to the activity of rifampicin [87]. A small percentage of
rifampicin resistance occurs through mechanisms other than the well-characterized target, β subunit
of RNA polymerase. Proteomic profiling of rifampicin-treated M.tb resulted in the under-expression
of four proteins implicated in cell wall biosynthesis (Ino1, FabD, EsxK and PPE60), suggesting
that rifampicin also affects cell wall synthesis contributing to bacterial death. The authors used
a liquid chromatography-mass spectrometry (LC-MS) approach, assessing small changes to the
M.tb proteome temporally. Consideration should be taken when conducting such experiments
to minimize the introduction of false-positives as a result of weak signals from an analytical
column coupled with a highly sensitive detection platform. Despite these limitations, the authors
reported a protein coverage comparable to other studies that applied nano-liquid chromatography.
Nano-liquid chromatography is becoming an established tool for advanced peptide separation that uses
very narrow columns that are more effective for detecting low abundance compounds [88]. Similarly,
proteomics has been utilized to discern the mode of action of repurposed drugs that inhibit M.tb in vitro.
Sulfamethoxazole, a broad-spectrum antibiotic that primarily targets the folate biosynthesis pathway,
exhibits a synergistic effect when combined with other anti-TB drugs. Sarkar et al. mapped the M.tb
response to sulfamethoxazole exposure using proteomics, identifying induction of oxidative stress
and electron transport chain pathways that suggested an additional mode of action for this drug [89].
Proteomics may also be exploited to determine mechanisms of drug resistance. Putim et al. employed
a shotgun proteomics system to identify proteins secreted in isoniazid- and rifampicin-resistant M.tb
compared to drug-sensitive M.tb. Bacterial cultures were filtered through low binding protein-cellulose
acetate membranes to collect culture filtrate proteins, before sodium dodecyl sulphate-polyacrylamide
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gel electrophoresis (SDS-PAGE), in-gel digestion and LC-MS. Depending on the aim of the study,
consideration in the liquid chromatography (LC) approach should be taken. For example, for high
proteome coverage, or for detecting proteins in low abundance, a 1D gradient for 8 h or a 2D LC
should be used. However, for analysis of a limited sample volume, or where characterization of
low-abundance proteins is not needed, a 1D gradient for 4 h may suffice. In addition, reproducibility
and sample requirements will vary greatly depending on the method used [90]. Differential abundance
of proteins involved in lipid metabolism, proteasome function and ATP-binding cassette transporters
(ABC transporters) between drug-resistant and drug-sensitive strains may reveal novel systems that
influence drug efficacy [91].
5. Metabolomics
5.1. Target Identification
Metabolomics, the analysis of the metabolite network within a biological system, is an indispensable
omics approach for drug discovery, providing information on the potentially druggable processes
occurring in a cell. Metabolomics in a discovery biology setting has elucidated M.tb metabolic pathways
in use in different microenvironments. Carvalho et al. supplemented cultures grown aerobically at 37 ◦C
with different 13C-labelled carbon substrates followed by LC-MS to separate and identify metabolites,
demonstrating that M.tb co-catabolizes multiple carbon sources simultaneously, through glycolytic,
pentose phosphate and tricarboxylic acid pathways [92]. For example, during co-catabolism of dextrose
and acetate, dextrose was preferentially metabolized into intermediates of glycolysis and the pentose
phosphate pathway, whereas acetate was preferentially used for tricarboxylic acid cycle (TCA cycle)
intermediates. This understanding of the M.tb metabolic network will help to delineate key pathways
and essential metabolites that could be exploited as therapeutic targets. More recently, Serafini et
al. used a similar approach to elucidate the metabolic pathways involved in the assimilation of
pyruvate and lactate in M.tb. Although it is well-established that lipids are important carbon sources
for M.tb during infection, the authors demonstrated a novel function for the methylcitrate cycle,
highlighting that it could be reversed for the biosynthesis of propionyl-CoA and the metabolism
of pyruvate and lactate, identifying new targets for drug discovery efforts [93]. This study is an
excellent example of a multi-omics approach, combining transposon-directed insertion site sequencing,
RNAseq transcriptomics, proteomics and metabolomics, enabling an multi-analyte functional overview
of the carbon metabolism network in M.tb.
Agapova et al. coupled stable isotope tracing of labelled amino acids with mass spectrometry
to elucidate the use of amino acids as a nitrogen source in M.tb [94]. The authors showed that the
co-metabolism of multiple amino acids as nitrogen sources did not improve growth compared to
metabolism of a single source. In addition, several amino acids were utilized as sole nitrogen sources
much faster than ammonium, suggesting that M.tb preferentially metabolizes specific host amino acids
as sources of nitrogen. As such, metabolomics provided insight into the potential for targeting specific
pathways in the M.tb nitrogen metabolic network. The authors also suggested that greater emphasis
should be placed on amino acids as sole carbon sources to better mimic physiologically relevant
conditions found in the host. Borah et al. used 15N-flux spectral ratio analysis to demonstrate that M.tb
in macrophages has access to multiple amino acids for nitrogen metabolism and identified serine as an
amino acid not available to intracellular bacilli [95]. The proteinogenic amino acid serine that provides
the nitrogen backbone for glycine and cysteine synthesis must be synthesized by intracellular M.tb,
highlighting this pathway, and phosphoserine transaminase in particular, as a novel target for drug
discovery. In a similar target identification application, Dutta et al. used metabolomics to confirm
the role of the stringent response regulator Rel in controlling transition to non-replicating states by
comparing wild type M.tb with an M.tb knockout strain lacking RelMtb, verifying Rel as a potential
anti-TB drug target. The authors then screened a library of compounds against this target, identifying
lead compounds that killed nutrient-starved M.tb [96].
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5.2. Mode of Action
The utility of metabolomics is demonstrated in studies to elucidate the mode of action of novel
compounds. In a high-throughput metabolomics approach, Zampieri et al. evaluated mass spectra
of supernatants from drug-treated M. smegmatis cultures to profile a library of 212 antimycobacterial
compounds with unknown modes of action [97]. The metabolomic signatures were first established
for 62 reference compounds with 17 known targets, before assessing similarity to the test compound
profiles. Over 70% of the 212 compounds could be classified with a known mechanism of action,
whilst 16 compounds resulted in metabolomic profiles dissimilar to the reference compounds. Of these
16 compounds, 6 exhibited a similar metabolomic response suggestive of the inhibition of lipid and
trehalose metabolism. This approach revealed new druggable pathways in M.tb, and importantly
enables drug discovery programs to diversify target pathways, discarding molecules that likely inhibit
targets of existing drugs. In this study, the compounds with unknown mechanisms of action exhibited
modest inhibitory activity against M. smegmatis with unique metabolic patterns that likely reflect
specificity in their underlying modes of action. Whilst further studies should be directed at assessing
the activity and mechanism of action of these compounds in M.tb, this study clearly demonstrates the
utility of this approach to recognize compounds that target novel pathways. In a similar approach,
untargeted metabolite profiling using flow infusion electrospray ion high resolution mass spectrometry
was used to explore the mode of action of pretomanid [98]. The M. smegmatis metabolite profile
after exposure to pretomanid was distinct when compared to ampicillin, ethambutol, ethionamide,
isoniazid, kanamycin, linezolid, rifampicin and streptomycin-treated cultures. Mapping of differentially
abundant metabolites onto pathways highlighted the pentose phosphate pathway, suggesting that
accumulation of the toxic metabolite methylglyoxal may contribute to the antibacterial activity of
pretomanid. A recent LC-MS-based metabolic linkage analysis of bedaquiline-treated M.tb revealed
that, alongside inhibition of ATP synthase, glutamine metabolism was also impacted. Since glutamine
synthesis inhibitors were synergistic in combination with bedaquiline, an indirect secondary effect of
bedaquiline on glutamine biosynthesis was distinguished that could be targeted therapeutically [99].
These approaches demonstrate how metabolomics may be used to elucidate the action of unknown
drugs, and reveal fundamental information about the physiology of M.tb.
6. Lipidomics
6.1. Target Identification
Mycobacteria have unique cell envelopes, high in lipid diversity and abundance, comprising up
to 40% of the bacillus dry weight [100]. Cell wall biosynthetic pathways are the target of many existing
anti-TB drugs; in addition, the sequencing of the M.tb genome revealed many lipid biosynthesis and
polyketide synthase genes that might be exploited as potential therapeutic targets. The study of this
network of cellular lipids within a biological system is broadly categorized in a branch of metabolomics,
known as lipidomics, which examines lipid species that are present and how they interact with other
lipids, metabolites and proteins in a cell [101]. Lipidomics relies on mass spectroscopy, measuring the
mass-to-charge ratio and abundance of gas-phase ions, further characterized into gas chromatography
(GC)-MS, liquid chromatography (LC)-MS and direct infusion-MS [102]. The large diversity of lipids
and the lack of spatial information about the distribution of these moieties within a cell complicates the
inferences from lipidomic experiments [103]. Lipidomics has been employed to discover potentially
druggable lipid biosynthesis pathways based on the M.tb response to the changing environment.
Raghunandanan et al. determined the pattern of M.tb lipid changes in hypoxia-induced dormancy and
resuscitation, showing that lipid concentration drastically decreased during dormancy and gradually
increased again during re-aeration [104]. Several lipids were more abundant in non-replicating
bacteria, revealing potentially targetable pathways [104]. This study demonstrates the potential
of lipidomics to evaluate M.tb in vitro in conditions predicted to mimic in vivo microenvironments.
Compared to conventional high performance-LC, the ultra-performance LC technique provided a much
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greater chromatographic resolution and subsequently faster analysis time [105]. Lipidomics is also
a valuable tool to characterize lipid biosynthetic pathway targets. The fatty acid synthase FAS-II
multi-enzyme system is essential for the biosynthesis of mycolic acids and normal cell wall function in
mycobacteria. It is the target of several antimycobacterial drugs, such as isoniazid, and therefore offers
additional therapeutic potential. To understand the role of HadD, a novel FAS-II enzyme, Lefebvre et
al. analyzed total extractable lipids from M. smegmatis hadD knockout mutants by high-performance
thin-layer chromatography to demonstrate that hadD deletion resulted in the absence of α- and
epoxy-mycolic acids that disrupted the cell envelope and reduced bacterial fitness [106]. Subsequently,
the authors showed that hadD deletion in M.tb resulted in a 63% reduction in keto-mycolic acids,
while overexpression of hadD induced an 87% increase in keto-mycolic acids compared to wild type.
Knockout mutants of hadD were attenuated in a murine model of infection, confirming hadD as a new
target for drug discovery [107].
6.2. Mode of Action
Sharma et al. demonstrated the role for lipidomics in mechanism of action studies by mapping the
impact of the natural antimycobacterial compound vanillin in M. smegmatis. The authors observed that
vanillin changes the composition of fatty acids, glycolipids, glycerophospholipids and saccharolipids
causing disruption of cell membrane homeostasis [108]. Similarly, lipidomic analysis has been
instrumental in investigating the consequences of M.tb drug-resistance conferring mutations to
well-characterized anti-TB drugs [109]. Howard et al. demonstrated that rifampicin-resistant M.tb
isolates with mutations in rpoB exhibited altered lipid profiles dependent on the specific location of the
SNPs [109]. Lipidomic analysis showed that different rpoB SNPs resulted in distinct relative abundances
of short-chain and long-chain fatty acid phthiocerol dimycocerosates (PDIM), which induced alternative
macrophage activation pathways and altered macrophage metabolism. Such analyses are useful not
only to understand the mode of action of a compound, but to deconvolute the consequences of drug
resistance-conferring mutations. Lipidomics is often used as an unbiased approach to complement
findings from other methodologies. An example is the evaluation of the mycolic acid transporter,
MmpL3, as a druggable target [110]. MmpL3 is an integral inner membrane transporter, with a role in
the export of mycolic acids to the periplasmic space in the biosynthesis of the mycobacterial cell wall.
Lipidomic analysis of mmpL3 M.tb knockdown mutants using thin layer chromatography of total lipids
revealed a fast decline in cell wall-bound mycolic acids and trehalose dimycolates. Combined with
confirmation of in vitro and in vivo essentiality, this study confirmed the mycolic acid transporter
MmpL3, as a validated druggable target for M.tb drug discovery. Similarly, lipidomics, alongside
genomics and transcriptomics, characterized the mode of action of HC2091, a novel compound that
likely targets MmpL3. M.tb HC2091-resistant mutants were shown to have SNPs in the mmpL3
gene, likely conferring drug resistance. Thin layer chromatography of the total extractable lipids
from HC2091-treated M.tb cultures supplemented with radiolabelled-sodium acetate demonstrated
a dose-dependent reduction in trehalose dimycolate accumulation with increasing concentration of
HC2091. In combination with transcriptional profiling of HC2091-treated bacilli, the authors confirmed
that HC2091 targets MmpL3 through a mechanism distinct from other MmpL3 inhibitors [66].
Lipidomics, therefore, often in combination with other omics approaches, is an effective tool, especially
in the interrogation of cell wall biosynthetic pathways, a rich source of druggable M.tb targets.
7. Future Outlook and Conclusions
This review has focused on established mycobacterial omics technologies and their application to
the early stages of M.tb drug discovery. New omics are emerging that will contribute to future drug
development; for example, glycomics, the study of all glycans in a biological system. Glycans are vital
in a broad range of processes, their direct recognition by glycan-binding proteins is important for many
processes that may be essential and druggable. Recently, Kavunja et al. used a glycomics approach
to identify mycolate-interacting proteins associated with synthesis and remodeling of the membrane
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in M. smegmatis that could lead to the validation of novel therapeutic targets [111]. Such techniques
offer unique opportunities for biological discovery and new target identification that will expand as
methodologies develop to increase sensitivity and reduce complexity.
The strength of omics technologies is multiplied when used in combination to understand bacterial
metabolism and pathogenicity, leading to a true systems approach to antimicrobial drug discovery.
This requires the development and maintenance of bioinformatics tools, data repositories, integration
and visualization platforms. Recent initiatives in data-sharing not only showcase multi-omics
studies but also aim to make omics datasets more readily accessible to the research community [112].
Increased accessibility alongside significant reductions in the cost of omics technologies and advances
in data analysis platforms [113], both for data management and for improving ease-of-use, ensure
that omics are ubiquitous in drug discovery, preclinical and clinical development programs across
academia and pharma [114]. Where M.tb-focused omics technologies are combined with human omics
systems in a quantitative pharmacology approach to finding and delivering new therapeutics.
The unsupervised nature of omics approaches and the separation from a priori hypotheses places
omics technologies in unique and vital roles in the drug development process. For multi-omics to become
fully incorporated into the drug development pipeline the challenge remains to move more quickly
from initial target identification to target validation in target-based discovery, and in compound-first
approaches to scale up mode of action studies to integrate with medium/high-throughput screening.
Omics platforms have contributed significantly to the development of the most recent M.tb drugs
brought to market and to multiple drug candidates now in clinical trials, alongside providing insights
into M.tb physiology, drug action and drug resistance. Omics methodologies have become valuable
tools in the search for new antimicrobial drugs that are becoming increasingly important to find.
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